SUNPHARMA Sun Pharmaceuticals Industries Ltd Legal Disputes Announcement 2023 - Regulatory Compliance Sun Pharmaceutical Industries announced that the US FDA has placed the IND on partial clinical hold for its Deuruxolitinib (CTP-543) due to potential thrombotic events at the 12 mg BID dose in one of the long-term Open Label Extension (OLE) studies, requiring the subjects currently on the 12 mg BID dose in the OLE studies to discontinue that dose..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Sun Pharmaceuticals Industries Ltd